{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:19:40Z","timestamp":1772493580940,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17\/19) were virally suppressed (&amp;lt;200\u2005copies\/mL) within 1 year of receiving B\/F\/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf588","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:51:04Z","timestamp":1758628264000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Efficacy of Crushed Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Administered via Tube"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4833-3073","authenticated-orcid":false,"given":"Joshua","family":"Mercure","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital , Boston, Massachusetts 02114 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3220-9785","authenticated-orcid":false,"given":"Kayla","family":"Bey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital , Boston, Massachusetts 02114 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-8526","authenticated-orcid":false,"given":"Eric","family":"Gillett","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Brigham and Women's Hospital , Boston, Massachusetts 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-1050","authenticated-orcid":false,"given":"Jeffrey C","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Brigham and Women's Hospital , Boston, Massachusetts 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M","family":"McCluskey","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2067-4673","authenticated-orcid":false,"given":"Alex E","family":"Rock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital , Boston, Massachusetts 02114 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2025102314050784100_ofaf588-B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society\u2013USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"2025102314050784100_ofaf588-B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"2025102314050784100_ofaf588-B3","first-page":"365","article-title":"Clinical pharmacology of the single tablet regimen bictegravir\/emtricitabine\/tenofovir alafenamide in the evolving era of antiretroviral therapies","volume":"27","author":"Perri","year":"2019","journal-title":"Infez Med"},{"key":"2025102314050784100_ofaf588-B4","first-page":"126","article-title":"When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection","volume":"19","author":"Nyberg","year":"2016","journal-title":"Top Antivir Med"},{"key":"2025102314050784100_ofaf588-B5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.coviro.2011.10.020","article-title":"Drug resistance in HIV-1","volume":"1","author":"Kuritzkes","year":"2011","journal-title":"Curr Opin Virol"},{"key":"2025102314050784100_ofaf588-B6","doi-asserted-by":"crossref","first-page":"ofae213","DOI":"10.1093\/ofid\/ofae213","article-title":"Managing modern antiretroviral therapy in the intensive care unit: overcoming challenges for critically ill people with human immunodeficiency virus","volume":"11","author":"Chastain","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025102314050784100_ofaf588-B7","doi-asserted-by":"crossref","first-page":"ofad554","DOI":"10.1093\/ofid\/ofad554","article-title":"Evaluation of dolutegravir- and bictegravir-based antiretroviral regimen utilization in patients who cannot take medications by mouth","volume":"10","author":"LoFaso","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025102314050784100_ofaf588-B8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkac369","article-title":"Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study","volume":"78","author":"Hocqueloux","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025102314050784100_ofaf588-B9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/1060028020953631","article-title":"Successful bictegravir\/emtricitabine\/tenofovir alafenamide treatment in a HIV patient with swallowing difficulties","volume":"55","author":"Ferr\u00e1ndez","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2025102314050784100_ofaf588-B10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/09564624211048702","article-title":"Crushed bictegravir\/emtricitabine\/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer","volume":"33","author":"Roa","year":"2022","journal-title":"Int J STD AIDS"},{"key":"2025102314050784100_ofaf588-B11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ajhp\/zxaa017","article-title":"Crushed bictegravir\/emtricitabine\/tenofovir alafenamide in a human immunodeficiency virus\u2013positive patient with esophageal cancer","volume":"77","author":"Fulco","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025102314050784100_ofaf588-B12","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15994","article-title":"Enteral administration of crushed rilpivirine in a patient with HIV: a case report","author":"Ragonnet","year":"2024","journal-title":"Brit J Clinical Pharma."},{"key":"2025102314050784100_ofaf588-B13","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/ajhp\/zxac120","article-title":"Increased viral load in a hospitalized patient on treatment with crushed bictegravir\/emtricitabine\/tenofovir alafenamide: a case report and review of the literature","volume":"79","author":"Rowe","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2025102314050784100_ofaf588-B14","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient","volume":"179","author":"Lozano","year":"2020","journal-title":"Antiviral Res"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf588\/64358442\/ofaf588.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf588\/64358442\/ofaf588.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf588\/64358442\/ofaf588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:05:14Z","timestamp":1761242714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf588\/8262682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf588","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,24]]},"article-number":"ofaf588"}}